

## Washington Hospital - Active Phase III Clinical Trials

Cancer Site	Clinical Trial Title	Protocol ID(s)	ELIGIBILITY*
<b>Breast</b>	Doxorubicin, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer	E5103	Significant risk of distant recurrence based on $\geq 1$ of the following criteria: - At least 1 axillary lymph node positive on routine histologic examination (must be demonstrated by more than immunohistochemistry alone) - Estrogen receptor (ER)-negative tumor $\geq 1$ cm - ER+ tumor $\geq 5$ cm regardless of recurrence score - ER+ tumor $\geq 1$ cm but $< 5$ cm with a recurrence score $\geq 11$
<b>Breast</b>	Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial)	PACCT-1	Estrogen and/or progesterone receptor positive tumor Her2/neu negative Lumpectomy or mastectomy plus axillary procedure within the past 84 days Tumor size 1.1-5.0 cm Tumors that measure 5 mm-1.0 cm are allowed provided there are unfavorable histological features, defined as intermediate or poor nuclear and/or histologic grade or lymphovascular invasion
<b>Breast</b>	Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer	NSABP B 42	Stage I, II, or IIIA primary tumor for patients who received neoadjuvant chemotherapy Received adjuvant hormonal therapy after breast cancer diagnosis for a duration of 57-63 months from the first dose (regardless of the number of missed doses) with 1 of the following: Must have completed adjuvant hormonal therapy within the past 6 months
<b>Breast</b>	Zoledronate, Clodronate, or Ibandronate in Treating Women Who Have Undergone Surgery for Stage I, Stage II, or Stage III Breast Cancer	S0307	Stage I-III disease Must have undergone lumpectomy or total mastectomy for primary disease within the past 12 weeks, or have completed chemotherapy within the past 8 weeks
<b>Colon</b>	Oxaliplatin, Leucovorin, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer	E5202	Stage II disease (T3-4, N0, M0)
<b>Prostate</b>	Radiation Therapy in Treating Patients With Stage II Prostate Cancer	RTOG 0415	Clinical stage T1-2c Combined Gleason score 2-6 Prostate-specific antigen (PSA) $< 10$ ng/mL within the past 6 months
<b>Prostate</b>	Hormone Therapy and Radiation Therapy or Hormone Therapy and Radiation Therapy Followed by Docetaxel and Prednisone in Treating Patients With Localized Prostate Cancer	RTOG 0521	Histologically confirmed prostate cancer at high-risk for recurrence within the past 180 days as determined by 1 of the following combinations (risk groups): Gleason score $\geq 9$ , prostate-specific antigen (PSA) $\leq 150$ ng/mL, and any T stage Gleason score 8, PSA $< 20$ ng/mL, and stage $\geq T2$ Gleason score 8, PSA 20-150 ng/mL, and any T stage Gleason score 7, PSA 20-150 ng/mL, and any T stage Clinically negative lymph nodes by imaging PSA $\leq 150$ ng/mL No distant metastases by physical exam and bone scan

\*Not a complete list of eligibility criteria

**Contact name:** Marianne Heltzel. (510) 745-6433. marianne\_heltzel@whhs.com